enGene Therapeutics Inc. (ENGN) bonds
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
Debt
Borrowings on the balance sheet, Jul 31, 2026
Total debt
$25.16M
Long-term debt
Net debt
-$15.87M
After $41.03M of cash
Implied interest rate
15.84%
FY2025 interest ÷ average debt
Interest coverage
-41.1×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in enGene Therapeutics's 10-Q for the period ended Jul 31, 2026
| Issue | Matures | Carrying value |
|---|---|---|
| 2026 Term Loan | Jan 1, 2030 | $27.73M |
| 2021 Loan and Security Agreement | – | $24.57M |
| Term Loan | – | $27.73M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?